La Roche-Posay suggests that you visit a skincare physician for a professional skin diagnosis to ensure that this product best addresses your skin’s needs.
The first and only product to combine a derivative of Salicylic Acid with Benzoyl Perozide in one effective formula.
Recommended For
Acne prone skin with localized acne breakouts
Product Information
The first and only product to combine a derivative of Salicylic Acid with Benzoyl Perozide in one effective formula.
Effaclar AI has been rigorously formulated with: 5.5% benzoyl peroxide acne medication to target acne deep in the pores to help control and correct breakouts. 0.4% LHA to micro-exfoliate the skin and stimulate cell renewal to help prevent residual marking. Oil-free formula is absorbed easily, leaving skin comfortable.
Benefits
Visibly reduces inflammatory lesions by 60%
Powerful acne medication in a breakthrough formula
Helps prevent flares of acne
Pro-exfoliating activity to help prevent residual skin discoloration
Non-comedogenic
Paraben free
Tested on sensitive skin
Can be used under makeup
Clinical studies
60% reduction in inflammatory lesions (pustules) in 10 days*
60% reduction in non-inflammatory lesions (closed-comedones) in 10 days*
Key Ingredients
Lipo-Hydroxy-Acid (LHA) > An exclusive pro-exfoliating molecule 6X more effective in kertaloytic action than salicylic acid alone
Micronized Benzoyl Peroxide > Acne medication to inhibit production of p.acnes bacteria in a micronized form to minimize irriation
Disclaimer
* Test conducted on 30 subjects, from 18 to 45 years old, 50% with self-perceived sensitive skin.
Inclusion criteria: At least 5 inflammatory and 10 retentional lesions.
Application of Effaclar AI to affected areas 1 to 3 times daily during 10 days.
Clinical evaluation: counting lesions +Overall Global Acne assessment + tolerance grading under dermatological control.
